Biotest will continue to develop as a global provider of biological pharmaceuticals in the therapeutic areas of haematology, clinical immunology and intensive care medicine. Our goal is to offer drugs that set benchmarks for efficacy, tolerability and convenience. This is valid for our already authorised preparations, as well as for all new developments. Quality is our highest purpose.
Based on our product portfolio and the gradual expansion of our international presence, we want to consistently take advantage of the opportunities available in our markets to sustainably increase the value of the company.